This study is an observational real-world research conducted on Chinese hepatocellular carcinoma (HCC) patients. Its primary objective is to evaluate the safety and efficacy of immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions.
Hepatocellular carcinoma exhibits a significantly elevated incidence and mortality rate in China. Despite the Chinese population representing a mere 18.4% of the global population, the annual incidence of new liver cancer cases reaches a staggering 466,000 (55.4% of the global total), with 422,000 deaths (53.9% of the global total). Immunotherapy, particularly the implementation of immunotherapy-based combination treatment regimens, holds substantial therapeutic value in the management of hepatocellular carcinoma (HCC), leading to notable breakthroughs and advancements in the comprehensive treatment of liver cancer. The aim of this study is to evaluate the safety and efficacy of immunotherapy-based combination treatment regimens in Chinese hepatocellular carcinoma (HCC) patients under real-world clinical conditions. By collecting and analyzing data on the etiology, clinical characteristics, treatment modalities, and treatment outcomes of HCC patients receiving immunotherapy-based combination treatments in the clinical healthcare setting, the study seeks to provide valuable information regarding treatment patterns and effectiveness for hepatocellular carcinoma patients.
Study Type
OBSERVATIONAL
Enrollment
11,000
immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions
Jiangsu Province Hospital
Nanjing, Jiangsu, China
RECRUITINGAdverse events
All adverse events during the course of the study treatment.
Time frame: 24 months
Progression free survival
From date of admission until the date of first documented progression in the real-world setting or date of death from any cause, whichever came first, assessed up to 24 months.
Time frame: 24 months
Disease control rate
The percentage of subjects achieving complete response, partial response, or disease stability in a real-world clinical setting.
Time frame: 24 months
Objective response rate
The percentage of subjects achieving complete or partial response in a real-world clinical setting.
Time frame: 24 months
Duration of response
The time from the first documentation of objective response to the first assessment of progression in the real-world setting.
Time frame: 24 months
Overall survival
From date of admission until the date of death from any cause, assessed up to 24 months.
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.